Addex Therapeutics Ltd (NASDAQ:ADXN – Get Free Report) was the target of a significant decrease in short interest in the month of June. As of June 15th, there was short interest totalling 4,700 shares, a decrease of 27.7% from the May 31st total of 6,500 shares. Based on an average daily volume of 18,600 shares, the days-to-cover ratio is presently 0.3 days. Currently, 0.6% of the company’s stock are sold short.
Addex Therapeutics Trading Up 0.7 %
Shares of ADXN stock opened at $8.22 on Friday. The company has a market capitalization of $8.71 million, a PE ratio of -0.48 and a beta of 1.78. The firm has a fifty day simple moving average of $9.43 and a 200-day simple moving average of $10.44. Addex Therapeutics has a twelve month low of $5.00 and a twelve month high of $27.90.
Addex Therapeutics (NASDAQ:ADXN – Get Free Report) last posted its quarterly earnings data on Thursday, June 6th. The company reported ($1.37) EPS for the quarter. Addex Therapeutics had a negative net margin of 818.50% and a negative return on equity of 364.24%. The company had revenue of $0.27 million for the quarter. Equities research analysts predict that Addex Therapeutics will post -11.8 EPS for the current year.
Institutional Inflows and Outflows
About Addex Therapeutics
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder.
See Also
- Five stocks we like better than Addex Therapeutics
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- Qualcomm Stock: AI-Powered Growth Despite Volatility
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- Salesforce Stock: Meeting Recap, AI Focus, and Forecast
- With Risk Tolerance, One Size Does Not Fit All
- Is CAVA Overextended? A Closer Look at This High-Flying Stock
Receive News & Ratings for Addex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Addex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.